drugset / Trial / NCT04580394
Crossover Trial of AD109 in Obstructive Sleep Apnea
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a randomized, 4-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of AD109 versus its individual components or placebo in patients with obstructive sleep apnea.
Timeline
- Start
- 2020-10-27
- Primary completion
- 2021-05-28
- Completion
- 2021-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AD109 | Unknown | — | Oral |
| Comparator | Aroxybutynin | Small molecule | — | Oral |
| Comparator | Atomoxetine | Other / unclassified | — | Oral |